A 68-year-old woman developed allergic contact dermatitis to topical metronidazole gel as proven by positive patch tests to the gel and to metronidazole. She was also allergic to methylchloroisothiazolinone and methylisothiazolinone (MC ⁄ MI). The similarity between the two molecules and the fact that the patient reacted to the gel after the very short incubation period of 1 day (i.e. not long enough for acquiring an active sensitization) makes the possibility of a cross-reaction between these substances very plausible. As the isothiazolinones are widely used and comprise an important and relatively frequent cause of allergic contact dermatitis, a cross-reactivity with metronidazole means that perhaps there should have been more cases of metronidazole allergy is more common than the current literature suggests.
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Report
Metronidazole, a widely used synthetic antiprotozoal and antibacterial agent, is generally well tolerated. There have, however, been isolated reports on cutaneous adverse reactions to the drug, among them immediate allergic reactions and urticaria, 1, 2 acute generalized exanthematous pustulosis, 3, 4 and serum sickness 5 as well as several cases of fixed drug eruption. [6] [7] [8] [9] [10] [11] [12] [13] Topical use of metronidazole gel has been reported to cause burning, stinging, redness, irritation, itching, or worsening of rosacea. In clinical trials, individual events occurred in less than 10% of patients treated (http:// www.metrogel.com/index.cfm). True allergic contact dermatitis from topical use of metronidazole is extremely rare. 14 We report a case of allergic contact dermatitis to topical metronidazole gel confirmed by positive patch tests, and discuss the possibility of there having been a cross-reaction with isothiazolinone in our patient.
A 68-year-old woman presented with an erythematous itchy eruption of 5 days' duration on her face. She had received metronidazole topical gel 0.75% (Rozex Gel, Galderma) for the treatment of mild rosacea expressed by only two to four pustules according to her testimony. She had no history of any skin disease or of any allergy. On examination, she had a severe bright red erythema around her mouth, on her nose reaching the nasal parts of her cheeks and on her upper and lower eyelids, with multiple pustules around her mouth, characteristic of acute contact dermatitis.
We prescribed doxycycline 100 mg per day and wet dressings on her face. There was significant improvement of the eruption within 1 week, but she still had small, red, dry, scaly papules, mainly around her mouth, typical to subacute dermatitis, with several pustules on top of them, remnants of rosacea.
Patch testing was performed with the European standard series and the cosmetic series (all from Chemotechnique Diagnostics, Malmo, Sweden). Two positive (++D2 and +++D3) reactions to a mixture of methylchloroisothiazolinone and methylisothiazolinone (MC ⁄ MI) in the standard and the cosmetic series were observed, which were also positive (+++) 1 week later. We then performed closed patch tests with Rosex Gel (0.75% metronidazole) and with a solution of metronidazole 0.5% (0.5G ⁄ 100 mL) for intravenous injection which is commercially available at (Flagyl Injectable, Specia). Positive reactions (+) for the Gel and + ⁄ ++ for the solution were observed at D2 and D3. According to R.T. Plott, director of Worldwide Clinical Development for Galderma Laboratories a 0.75% metronidazole cream has been patch tested in 200 subjects, four of whom had reactions that were determined to be irritant reactions to benzyl alcohol on testing with the constituent ingredient (cited in Watsky). 3 We report an unusual case of true allergic contact dermatitis to topically applied metronidazole. The allergy was proven to be to the active ingredient of the product. The patient was also allergic to MC ⁄ MI as demonstrated by strong reactions in patch tests.
These findings raise the question of whether the reactions to the two substances are merely a coincidence, occurring in a patient who happened to have two unrelated allergies, or whether we are dealing with a cross-reaction. Although the answer to this question cannot be derived from the available data, the similarity between the two molecules ( Fig. 1) and the fact that the patient reacted to the gel after the very short incubation period of 1 day (i.e. not long enough to acquire an active sensitization) makes the possibility of a cross-reaction between these substances very plausible.
A cross-reaction between metronidazole and MC ⁄ MI, if such is the case, might have far-reaching and important implications, since the isothiazolinones are widely used and comprise an important and relatively frequent cause of allergic contact dermatitis. This would mean that we should expect to see many more cases of allergic reactions to metronidazole in the future. Actually, it is possible that many such cases have been overlooked by having been diagnosed as irritation from and ⁄ or intolerance to topical metronidazole or because the patients simply discontinued use of the product on their own volition. 
